A study to evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and preliminary Anti-Tumor activity of RO7616789 in participants with Advanced Small Cell Lung Cancer and other Neuroendocrine Carcinomas
BP44382
Phase 1 other active
Quick answer
A study to evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and preliminary Anti-Tumor activity of RO7616789 in participants with Advanced Small Cell Lung Cancer and other Neuroendocrine Carcinomas for Small Cell Lung Cancer and Neuroendocrine Carcinoma is a Phase 1 program (other) at Hoffmann-La Roche with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Hoffmann-La Roche
- Indication
- Small Cell Lung Cancer and Neuroendocrine Carcinoma
- Phase
- Phase 1
- Modality
- other
- Status
- active